Takeda Oncology Company has withdrawn its application for expanding the use of the drug Velcade to treat relapsed follicular lymphoma in combination with rituximab. The decision was made after disappointing results of the LYM-3001 trial published last July in Lancet Oncology. The study showed that combining Velcade with rituximab slowed the progression of relapsed follicular lymphoma by an median of 1.8 months or about 54 days. Velcade remains on the market for the treatment of mantle cell lymphoma.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment